Memorial Hospital Research Laboratories
The Michelle Bradbury Lab
I am a clinician-scientist with experience in the application of a wide range of molecular imaging tools in both preclinical and clinical settings. At Memorial Sloan Kettering, I direct a laboratory that focuses on the development, characterization, and evaluation of translational silica nanomaterials for cancer applications. We use these materials in conjunction with imaging tools (including PET and optical devices) to individualize patient care. In addition, my team explores the biological and chemical interactions of these materials at multiple spatial scales — from the cellular/molecular level to that of organs and tissues. We then link these findings to sites of disease using whole-body imaging studies of small animal models and humans.
Thulborn KR, Lu A, Atkinson IC, Pauliah M, Beal K, Chan TA, Omuro A, Yamada J, Bradbury MS. Residual Tumor Volume, Cell Volume Fraction, and Tumor Cell Kill During Fractionated Chemoradiation Therapy of Human Glioblastoma using Quantitative Sodium MR Imaging. Clinical Cancer. Research Published Online January 4th , 2019. Doi: 10.1158/1078-0432.CCR-18-2079.
Chen F, Ma K, Madajewski B, Zhuang L, Zhang L, Rickert K, Marelli M, Yoo B, Turker MZ, Overholtzer M, Quinn TP, Gonen M, Zanzonico P, Tuesca A, Bowen MA, Norton L, Subramony JA, Wiesner U, Bradbury MS. Ultrasmall targeted nanoparticles with engineered antibody fragments for imaging detection of HER2-overexpressing breast cancer. Nat Commun. 9(1):4141, 1-11, 2018.
Chen F, Zhang X, Ma K, Madajewski B, Benezra M, Zhang L, Phillips E, Turker MZ, Gallazzi F, Penate-Medina O, Overholtzer M, Pauliah M, Gonen M, Zanzonico P, Wiesner U, Bradbury MS, Quinn TP. Melanocortin-1 Receptor-Targeting Ultrasmall Silica Nanoparticles for Dual-Modality Human Melanoma Imaging. ACS Appl Mater Interfaces.10 (5):4379-4393, 2018.
Hartshorn CM, Bradbury MS, Lanza GM, Nel AE, Rao J, Wang AZ, Wiesner UB, Yang L, Grodzinski P. Nanotechnology Strategies To Advance Outcomes in Clinical Cancer Care. ACS Nano. 12(1):24-43, 2018.
Chen F, Ma K, Benezra M, Zhang L, Cheal SM, Phillips E, Yoo B, Pauliah M, Overholtzer M, Zanzonico P, Sequeira S, Gonen M, Quinn T, Wiesner U, Bradbury MS. Cancer-Targeting Ultrasmall Silica Nanoparticles for Clinical Translation: Physicochemical Structure and Biological Property Correlations. Chem Mater. 29(20):8766-8779, 2017.
Michelle S. Bradbury, MD, PhD
Director of Intraoperative Imaging, Radiology
- Clinician-scientist Michelle Bradbury develops translational, tumor-targeting, PET-optical silica nanoparticle probes for diagnostics, drug delivery, and sensing.
- PhD – Massachusetts Institute of Technology, Cambridge, MA
- MD – George Washington University, School of Medicine, Washington, DC
Get in Touch
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Michelle S. Bradbury discloses the following relationships and financial interests:
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2019 through disclosure submission in spring 2020). This data reflects interests that may or may not still exist. This data is updated annually.